Open Nav

Dr. Mintz brings a wealth of experience to his role as Chief Medical Officer at Verax. He is former president of the AABB who served as a tenured professor of Pathology and Medicine at the University of Virginia as well as Vice Chair of Pathology.

He also served on the AABB’s board of directors for nine years, and chaired and was a member of numerous AABB committees. Most recently, Dr. Mintz served as Director, Division of Hematology Clinical Review, Office of Blood Research and Review, Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration.


White Papers & Commentaries

  • Update to the Platelet PGD Test Eliminates Vast Majority of False Positive Reactions

    A recent minor product modification has resulted in a significant improvement in Platelet PGD Test specificity.  Validation testing of the minor modification to the PGD product demonstrated improved specificity performance and no loss in ability of the assay to detect bacteria. Overall observed specificity of the modified PGD Test was approximately 99.9% compared to overall specificity of 99.4% for the original PGD Test.

    Read the White Paper

  • Seven-Day Platelet Storage: Outdate Reduction and Cost Savings

    A recent presentation at the Annual Meeting of the Association of Clinical Scientists and the associated peer-reviewed published abstract document substantial cost savings and significant outdate reductions with the use of the PGD test to extend platelet dating to seven days.  Data from 66 hospitals and 16 blood collection centers are presented.  Implementing testing to extend storage saved more money than the testing cost.
    Read the Abstract

  • Limitations of Proposed Culture-Based Strategies in Detecting Bacterial Contamination of Platelets

    Three proposed culture methodologies intended to improve the performance of culture testing for bacterial contamination of platelets are reviewed in depth in this white paper. Available published and presented data are analyzed that call into question any improvement these approaches offer compared to the current US early culture protocol.
    Read the White Paper

  • Cost savings and outdate reduction with 7-day platelets

    A summary of the results of a recently performed user satisfaction survey of 50 users of the Platelet PGD Test. Besides providing an overview of all users experiences it focuses on the findings of 14 sites who have used the test to implement 7-day platelet dating. Those sites reported annual combined savings of $1.25 million due to outdate reduction with the PGD Test.
    Read the Survey Summary

  • Septic transfusion reaction associated with platelets contaminated with Staphylococcus Aureus

    A review of a case of sepsis due to platelet contamination reported by Canadian observers in an article recently published in the journal Transfusion. Interestingly, the authors observe that although very high levels of the Gram-positive species Staphylococcus aureus were present in the transfused unit, onset of sepsis was delayed by 2.5 hours after the platelet transfusion was started.
    Read the Article Review

  • The Verax Platelet PGD Test – FDA cleared indications for use and what they mean for your institution

    The Verax Platelet PGD Test has a broad range of FDA clearances to address whatever platelet types you may transfuse and now includes a new clearance for single units of whole blood derived platelets. In this report, we will review the specifics of each cleared indication for use and what this can mean for blood bank and transfusion service policies and procedures in your institution.
    Read the White Paper

  • WHO publishes list of bacteria for which new antibiotics are urgently needed thereby highlighting the requirement for further vigilance for platelet transfusions

    In this commentary on the list of “priority pathogens” recently published by the WHO, the very real risk that they could play an increasing role as platelet contaminants is explored.
    Read the Commentary

  • Verax Pan Genera Detection (PGD) test for platelet screening: A 5-year retrospective analysis in a high-volume transfusion service

    The first in a series of key poster and presentation reviews from the 2016 AABB Annual meeting. In this poster, Bracey and colleagues address implementing PGD in a large transfusion service and report their multiyear experience with the test’s low false positive rate.
    Read the Poster Review

  • PGD Testing All Platelets in a University Transfusion Service While Minimizing the Number of Tests Performed

    In this AABB Annual Meeting poster, Vauthrin and colleagues present the results of their experience performing the PGD test daily over a 2 year period observing a repeat rate of just 1.17 tests per platelet dose.
    Read the Poster Review

  • Implementing 7 Day Platelet Dating with the Platelet PGD® Test

    Hospitals and blood centers across the country are implementing 7-day platelet dating with the Platelet PGD Test in order to improve platelet availability, inventory management, and reduce wastage caused by outdating. This comprehensive review of the topic addresses training, validation, testing frequency, quality control, proficiency testing, information technology, FDA registration, AABB Standards, operational issues, labeling, and customer support resources. This report is a detailed and referenced how-to guide to assist in going live with 7-day platelet dating.
    Read the White Paper

  • The Inadequacy Of Passive Surveillance To Detect Septic Transfusion Reactions From Platelet Transfusion

    Septic transfusion reactions resulting from the transfusion of bacterially contaminated platelet components are a potentially fatal hazard of platelet transfusion. A review of the recent literature reveals just how ineffective passive surveillance is at recognizing when they occur and points the way towards active surveillance through testing as a better approach.
    Read the White Paper

  • Safety and Efficacy of Seven Day Platelets

    Recent FDA product approvals and a pathway outlined in draft FDA guidance have allowed the reintroduction of seven day platelet dating in the United States. But just how safe and effective are seven day platelets?  A review of published in vitro and in vivo studies reveals the current consensus.
    Read the White Paper

Have a question or comment? Click here to contact me directly.

Learn more about

"I'm excited to work at Verax because the company shares my passion for patient safety and best transfusion practices. I'll use this blog to express my thoughts and views about current topics in transfusion medicine and how they may impact your transfusion service or blood bank."

- Paul D. Mintz, MD

Hot Topics

New Final FDA Guidance recommends secondary testing with rapid tests and Safety Measure testing for 7-day dating
Learn More

CMS increases reimbursement for 2020 from $25.50 to $35.50 for code P9100 that can be used with the Platelet PGD Test
Learn More